Short Interest in ICU Medical, Inc. (NASDAQ:ICUI) Increases By 14.0%

ICU Medical, Inc. (NASDAQ:ICUI - Get Free Report) was the recipient of a significant growth in short interest in the month of January. As of January 15th, there was short interest totalling 838,100 shares, a growth of 14.0% from the December 31st total of 735,400 shares. Based on an average trading volume of 217,900 shares, the days-to-cover ratio is presently 3.8 days. Approximately 3.7% of the shares of the company are short sold.

ICU Medical Trading Up 0.3 %

Shares of NASDAQ:ICUI traded up $0.52 during mid-day trading on Wednesday, reaching $161.51. The stock had a trading volume of 117,306 shares, compared to its average volume of 205,458. ICU Medical has a twelve month low of $87.65 and a twelve month high of $196.26. The firm has a 50 day simple moving average of $160.86 and a two-hundred day simple moving average of $163.04. The firm has a market cap of $3.95 billion, a PE ratio of -35.34 and a beta of 0.63. The company has a current ratio of 2.29, a quick ratio of 1.03 and a debt-to-equity ratio of 0.75.

Insider Transactions at ICU Medical

In other ICU Medical news, CEO Vivek Jain sold 12,000 shares of the business's stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $162.91, for a total value of $1,954,920.00. Following the completion of the transaction, the chief executive officer now owns 104,593 shares in the company, valued at $17,039,245.63. The trade was a 10.29 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, COO Christian B. Voigtlander sold 1,962 shares of the business's stock in a transaction that occurred on Monday, November 25th. The stock was sold at an average price of $169.08, for a total transaction of $331,734.96. The disclosure for this sale can be found here. Insiders have sold 17,737 shares of company stock worth $2,879,752 over the last 90 days. 6.70% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On ICU Medical

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Hexagon Capital Partners LLC boosted its holdings in shares of ICU Medical by 162.7% in the 3rd quarter. Hexagon Capital Partners LLC now owns 197 shares of the medical instruments supplier's stock valued at $36,000 after purchasing an additional 122 shares in the last quarter. Allworth Financial LP boosted its holdings in ICU Medical by 100.0% in the third quarter. Allworth Financial LP now owns 200 shares of the medical instruments supplier's stock valued at $36,000 after acquiring an additional 100 shares during the last quarter. Venturi Wealth Management LLC raised its stake in ICU Medical by 1,510.0% during the third quarter. Venturi Wealth Management LLC now owns 322 shares of the medical instruments supplier's stock worth $59,000 after buying an additional 302 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of ICU Medical in the 2nd quarter valued at about $70,000. Finally, Point72 Hong Kong Ltd bought a new position in shares of ICU Medical during the 3rd quarter worth approximately $72,000. 96.10% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on the company. StockNews.com raised ICU Medical from a "hold" rating to a "buy" rating in a research report on Wednesday, November 20th. Jefferies Financial Group upgraded ICU Medical from a "hold" rating to a "buy" rating and set a $200.00 price objective for the company in a research report on Wednesday, December 11th. Needham & Company LLC restated a "hold" rating on shares of ICU Medical in a research note on Wednesday, November 13th. Finally, KeyCorp boosted their target price on shares of ICU Medical from $198.00 to $209.00 and gave the stock an "overweight" rating in a report on Wednesday, November 13th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat, ICU Medical has a consensus rating of "Moderate Buy" and a consensus price target of $199.67.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.